Ripasudil for Enhanced Corneal Clearing Following Descemet Membrane Endothelial Keratoplasty in Fuchs' Dystrophy
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
Recently, published literature has reported that performing a descemetorhexis in combination
with topical Rho kinase (ROCK) inhibitor therapy was successful in clearing edematous corneas
in patients with Fuchs Endothelial Corneal Dystrophy.
Ripasudil hydrochloride hydrate( Glanatec ophthalmic solution 0.4%), a potent ROCK inhibitor,
has been approved in Japan since 2014 for ocular use in the treatment of glaucoma. Ripasudil
acts as an IOP-lowering drug by affecting aqueous outflow through the trabecular meshwork and
Schlemm's canal.
The goal of this study is to test the potential benefits of Ripasudil therapy administered
after Descemet Membrane Endothelial Keratoplasty (DMEK) surgery. We believe that performing a
standard DMEK surgery in combination with Ripasudil treatment in patients with Fuchs
Endothelial Corneal Dystrophy could accelerate endothelial cell healing and clear edematous
corneas faster, with less post-operative complications.
Phase:
Phase 2
Details
Lead Sponsor:
Michael D. Straiko, MD
Collaborators:
Eye Bank Association of America Lions VisionGift Research